X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs BIOCON - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS BIOCON NOVARTIS/
BIOCON
 
P/E (TTM) x 422.6 18.9 2,231.1% View Chart
P/BV x 29.8 3.0 997.6% View Chart
Dividend Yield % 1.5 0.4 395.8%  

Financials

 NOVARTIS   BIOCON
EQUITY SHARE DATA
    NOVARTIS
Mar-18
BIOCON
Mar-18
NOVARTIS/
BIOCON
5-Yr Chart
Click to enlarge
High Rs7581,188 63.8%   
Low Rs579305 189.8%   
Sales per share (Unadj.) Rs228.468.7 332.3%  
Earnings per share (Unadj.) Rs31.77.6 420.3%  
Cash flow per share (Unadj.) Rs32.814.0 234.5%  
Dividends per share (Unadj.) Rs10.001.00 1,000.0%  
Dividend yield (eoy) %1.50.1 1,116.7%  
Book value per share (Unadj.) Rs297.186.3 344.1%  
Shares outstanding (eoy) m24.69600.00 4.1%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.910.9 26.9%   
Avg P/E ratio x21.198.9 21.3%  
P/CF ratio (eoy) x20.453.4 38.2%  
Price / Book Value ratio x2.28.6 26.0%  
Dividend payout %31.513.2 237.9%   
Avg Mkt Cap Rs m16,505447,900 3.7%   
No. of employees `0000.76.1 10.9%   
Total wages/salary Rs m1,4459,311 15.5%   
Avg. sales/employee Rs Th8,441.36,705.8 125.9%   
Avg. wages/employee Rs Th2,163.61,514.2 142.9%   
Avg. net profit/employee Rs Th1,173.1736.9 159.2%   
INCOME DATA
Net Sales Rs m5,63941,234 13.7%  
Other income Rs m1,7182,062 83.3%   
Total revenues Rs m7,35743,296 17.0%   
Gross profit Rs m-638,291 -0.8%  
Depreciation Rs m253,851 0.7%   
Interest Rs m55615 9.0%   
Profit before tax Rs m1,5755,887 26.8%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7921,569 50.5%   
Profit after tax Rs m7844,531 17.3%  
Gross profit margin %-1.120.1 -5.5%  
Effective tax rate %50.326.7 188.6%   
Net profit margin %13.911.0 126.5%  
BALANCE SHEET DATA
Current assets Rs m9,52241,486 23.0%   
Current liabilities Rs m3,29621,413 15.4%   
Net working cap to sales %110.448.7 226.8%  
Current ratio x2.91.9 149.1%  
Inventory Days Days3764 57.2%  
Debtors Days Days2894 30.2%  
Net fixed assets Rs m4650,661 0.1%   
Share capital Rs m1233,000 4.1%   
"Free" reserves Rs m7,21348,808 14.8%   
Net worth Rs m7,33651,808 14.2%   
Long term debt Rs m017,898 0.0%   
Total assets Rs m11,10599,897 11.1%  
Interest coverage x29.510.6 278.9%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.50.4 123.0%   
Return on assets %7.65.2 146.6%  
Return on equity %10.78.7 122.1%  
Return on capital %22.29.6 230.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6112,058 0.5%   
Fx outflow Rs m3,6307,348 49.4%   
Net fx Rs m-3,5704,710 -75.8%   
CASH FLOW
From Operations Rs m1,6106,621 24.3%  
From Investments Rs m687-6,840 -10.0%  
From Financial Activity Rs m-2,677-2,397 111.7%  
Net Cashflow Rs m-380-2,612 14.5%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 75.0 20.6 364.1%  
Indian inst/Mut Fund % 2.0 8.4 23.8%  
FIIs % 1.6 10.7 15.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 19.9 108.0%  
Shareholders   41,647 109,995 37.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   PANACEA BIOTECH  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 234 Points Higher; Healthcare and Realty Stocks Rally(Closing)

After opening the day on a flat note, Indian share markets witnessed buying interest during closing hours and ended higher.

Related Views on News

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

I Believe this is the Best Stock to Buy Today(Profit Hunter)

Jul 3, 2019

The languishing small cap space is currently offering a very fertile market to pick up bargains at very attractive prices. This is a perfect opportunity ripe for the picking.

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 16, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS